Ms. Yi-shuang Yang, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 1628 Medical Arts Blvd, Anderson, IN 46011 Phone: 765-649-5221 Fax: 765-649-1537 |
Elizabeth Lacy Groves-egan, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 1931 Brown St, Anderson, IN 46016 Phone: 765-644-1225 |
Dr. John D Jones, MD Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 1628 Medical Arts Blvd, Anderson, IN 46011 Phone: 765-649-5221 Fax: 765-649-1537 |
Nisha Shah Kheradiya, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 1931 Brown St, Anderson, IN 46016 Phone: 765-644-1225 |
Dr. Donald M Perez, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 141 W 22nd St, Suite 112, Anderson, IN 46016 Phone: 765-649-7146 Fax: 765-646-6042 |
News Archive
The U.S. health care system is famously resistant to government-imposed change. It took decades to create Medicare and Medicaid, mostly due to opposition from the medical-industrial complex. Then it was nearly another half-century before the passage of the Affordable Care Act.
GOP lawmakers hope to get back on the offensive in the Medicare debate. Ads will begin airing later this week that target a Democrat from Northern California, but some say the party needs to focus on a long-term strategy to regain its footing in this debate. Meanwhile, some House Democrats are pointing to a special congressional election in New York as proof that House Republican's Medicare vote is backfiring.
The use of growth hormone therapy has been linked in some people to the development of colon polyps, a possible precursor to colorectal cancer - but medical researchers have debated the extent of a cancer risk.
World Health Organization Director-General Margaret Chan in a letter to Thai Health Minister Mongkol na Songkhla said that although the Thai government was fully within its rights to issue a compulsory license for Abbott Laboratories antiretroviral drug Kaletra, countries should find the "right balance" between providing affordable medicines and incentives for drug companies to develop new treatments.
Complete Genomics, Inc. announced today that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission relating to the proposed initial public offering of shares of its common stock. The shares of common stock to be sold in this offering are proposed to be sold solely by Complete Genomics, Inc.
› Verified 3 days ago